This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Diartis Pharmaceuticals, Inc.

Drug Names(s): exenatide-XTEN

Description: VRS-859 is a once monthly form of the GLP-1 analog, exenatide, which incorporates Versartis's XTEN technology. XTEN is a novel hydrophilic sequence of natural amino acids and is expressed as a fusion protein with a therapeutically active peptide or protein. Per the company, use of XTEN leads to a relatively flat PK profile and is also expected to be less immunogenic than Byetta.

Deal Structure: In December 2008, Amunix and Index Ventures entered into a 50/50-owned joint venture called Versartis. Versartis licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.

In February 2011, Index Ventures and Amunix gave initial funding to Diartis Pharmaceuticals. Diartis acquired VRS-859 (exenatide-XTEN), and with this initial funding will continue its development for type 2 diabetes mellitus (T2DM).

Partners: Amunix, Inc.

VRS-859 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug